Form 4/A for URGN UroGen Pharma Ltd.
Accepted 2024-02-12 00:00:00 ET · period of report 2024-01-31 · accession 0001437749-24-003794 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2024-02-12 | 2024-01-31 | URGN | Kim Dong | CFO | M - OptEx | — | +3,333 | 35.3K | +10% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-01-31 | M | A | 3,333 | — | 35,253 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. (F2) This amendment corrects and restates the Amount of Securities Beneficially Owned Following Reported Transaction reported in the original Form 4 filed on February 2, 2024. |